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Copyright © 200? JCBN Summary Although low-dose aspirin is widely used, since it is a cheap and effective means
of prevention of cardiovascular events, it can cause hemorrhagic gastrointestinal complica-
tions. The aim of this study was to evaluate the efficacy of rebamipide in preventing low-dose
aspirin-induced gastric injury. A randomized, double-blind, placebo-controlled, crossover trial
was performed in twenty healthy volunteers. Aspirin 81 mg was administered with placebo or
rebamipide 300 mg three times daily for 7 consecutive days. The rebamipide group exhibited
significant prevention of erythema in the antrum compared with the placebo group
(p = 0.0393, respectively). Results for the body and fornix did not differ significantly between
the placebo and rebamipide groups. In conclusion, short-term administration of low-dose
aspirin induced slight gastric mucosal injury in the antrum, but not in the body or fornix.
Rebamipide may be useful for preventing low-dose aspirin-induced gastric mucosal injury,
especially which confined to the antrum.
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Introduction
Helicobacter pylori (H. pylori) infection [1] and the use
of non-steroidal anti-inflammatory drugs (NSAIDs) [2–4]
can cause gastrointestinal disease. We have reported that H.
pylori-negative, non-NSAID-induced gastrointestinal ulcers
are extremely rare [5]. Aging of the population has recently
been increasing in Japan, and long-term users of low-dose
aspirin are correspondingly increasing in number. Low-dose
aspirin is used for primary prevention of cardiovascular
events such as myocardial infarction. Randomized con-
trolled trials have demonstrated the preventive effect of
administration of low-dose aspirin for patients with prior
cardiovascular events [6–7]. Low-dose aspirin is widely
used, since it is a cheap and effective means of prevention
of cardiovascular events, and now over 5 million Japanese
undergo this treatment. However, aspirin use can have
hemorrhagic gastrointestinal complications. The recom-
mended dose of aspirin for the prevention of vascular events
is in the range of 75–300 mg/day, though when benefits and
risks are taken into account the optimal dose is considered
to be no more than 100 mg/day [8–10]. Few findings of
randomized, placebo-controlled trials are available to clearly
determine the risk of upper gastrointestinal ulcer with low-
dose aspirin. Several small trials, usually in healthy subjects,
have been performed, using a mucosal injury grading system
as an outcome measure [11–14]. The clinical utility of such
systems is uncertain, and these studies have not provided
specific findings on ulcer development.Preventing ASA-induced Gastric Injury
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Recently, a large 12-week endoscopic double-blind study
in osteoarthritis patients randomly assigned to placebo
(n = 381) or 81 mg enteric-coated aspirin (n = 387) found no
significant difference in rate of development of ulcer [15].
However, significant increases in mean number of erosions
(mean change: 0.2 vs 0.9) and in the proportion of patients
with increase in number of erosions (20% vs 32%) were
observed with low-dose aspirin. The increase in rate of
clinical events with low-dose aspirin is in general small. It
may also be that, though aspirin causes only a very slight
increase in rate of development of ulcer, the proportion of
patients with complications is much higher due to the anti-
platelet effects of aspirin. The increased risk of erosions
does indicate that some damage to the upper gastrointestinal
tract is occurring. In any case, the real issue in clinical
practice is determining the incidence of clinical gastro-
intestinal events, such as gastrointestinal bleeding, associated
with the long-term use of low-dose aspirin.
Rebamipide (2-(4-chlorobenzoylamino)-3-[2-(1H)-
quinolinon-4-yl]-propionic acid) (Otsuka Pharmaceutical
Co., Tokyo) is a mucosal-protective drug that has many
biological effects in the gastric mucosa, such as increasing
blood flow, increasing the biosynthesis of prostaglandins,
preventing  H. pylori-elicited neutrophil-induced mucosal
injury, and decreasing oxygen radical levels [16–19].
Rebamipide was also found to be efficacious in reducing
gastric injury in healthy subjects taking aspirin 1500 mg
once a day [20].
The aim of this study was to evaluate the efficacy of
rebamipide in preventing low-dose aspirin-induced gastro-
intestinal complications in healthy subjects.
Methods
A randomized, double-blind, placebo-controlled, cross-
over trial was performed in twenty healthy volunteers. The
study protocol was approved by the Ethics Committees of
Hokkaido University Hospital, and written informed consent
was obtained from all subjects.
Inclusion and exclusion criteria
Inclusion criteria were i) lack of gastric conditions such as
erosions, erythema, bleeding, and ulcer on endoscopy, and
ii) H. pylori negativity on 13C urea breath test. Subjects who
habitually smoked or drank alcohol were excluded.
Study design
The mean age of the 20 subjects was 24 ± 2 years; fifteen
were male and five were female. The 20 healthy subjects
were divided two groups, Group I and II. In the first period
of this study, aspirin 81 mg with placebo (Group I) or
rebamipide 300 mg (Group II) was administered three
times daily for 7 consecutive days, while in the second
period the two groups were crossed over. The washout
period is longer than two weeks between treatments (Fig. 1).
The 2-week washout period was determined with reference
to the life span of platelets and the half-lives of rebamipide
and aspirin.
Fig. 1. Study design.S. Ono et al.
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Evaluation criteria
Endoscopic gastric mucosal injury was determined in three
gastric areas, the antrum, body, and fornix. The categories of
injury were erythema, erosions, and petechiae. Erythema
was defined as an area clearly redder than surrounding
mucosa, petechia as a bleeding area without mucosal deficit,
and erosion as an area with mucosal deficit (Fig. 2). Gastric
mucosal injuries detected on endoscopy were evaluated by
Lanza score (Table 1).
Evaluation of adverse events
The following gastrointestinal symptoms and complica-
tions were to be recorded in the symptom diary by all
subjects over the entire study period.
Statistical analysis
Endoscopic gastric mucosal injuries were determined in
each gastric area, and analyzed by Fisher’s exact test.
Findings of p<0.05 were considered significant. All statistical
analyses were performed using SAS® version 8.2 (SAS
Institute, Cary, NC).
Results
Effects of treatment on endoscopically detectable gastric
mucosal injury
The effects of low-dose aspirin on endoscopically detect-
able gastric mucosal injury in the placebo and rebamipide
groups are shown in Tables 2 and 3. Lanza scores in the
antrum are shown in Table 2. The rebamipide group exhibited
significant prevention of erythema in the antrum, compared
with the placebo group (p = 0.0393). The incidence of
neither erosions nor petechiae differed significantly between
the placebo and rebamipide groups. The results of evaluation
of gastric mucosal injury in the body and fornix are shown
in Table 3. There were no significant differences between
the placebo and rebamipide groups.
Adverse events
No gastrointestinal symptoms or complications were
recorded in the symptom diary by any subjects during the
study period.
Conclusion
Recently, the number of individuals using low-dose
aspirin to prevent cardiovascular events has sharply increased
in Japan. Increase in the rate of occurrence of lethal bleeding
has been predicted with use of this treatment, though that of
cardiovascular events should be decreased with it. The
frequencies of aspirin-induced gastrointestinal bleeding and
ulcer are lower than those of NSAID-induced gastro-
intestinal bleeding and ulcer, though their severity is very
mild. Aspirin produces its anti-thrombotic effects through
irreversible acetylation of a serine in cyclooxynase-1 in
platelets [21]. This abolishes production of thromboxane A2
for the life of the platelet. Although the half-life of aspirin is
short, at 0.4 h, it suppresses platelet aggregation for almost 1
week [22, 23]. This 1-week period is due to the life span of
platelets. The effects of aspirin on platelets are a significant
problem for chronic aspirin users, compared with NSAID
users. Patients with a history of gastric bleeding, who take
corticosteroids, or who are elderly readily develop gastro-
intestinal bleeding [24]. Prevention of aspirin-induced
gastric bleeding, especially for high-risk groups, may thus
be necessary. Only for proton pump inhibitors is there
Fig. 2. Endoscopic findings of erythema (a), petechiae (b), and erosion (c).
Table 1. Lanza score.
0: Normal or erythema
1: mucosal hemorrhage only
2: one or two erosions ± submucosal hemorrhage or edema
3: numerous (3–10) erosions ± submucosal hemorrhage or edema
4: large number of erosions (>10) or an ulcerPreventing ASA-induced Gastric Injury
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evidence of prevention of aspirin-induced gastric bleeding
[25]. However, administration of long-term acid-suppressive
agents carries the risk of infection, such as ventilator-
associated pneumonia [26]. Candidate drugs other than
acid-suppressing agents are thus needed.
Two reports are available on the use of rebamipide in
healthy subjects with drug-induced gastric mucosal injury.
The efficacy of rebamipide in reducing NSAID-induced
gastric injury has been reported in healthy volunteers on
indomethacin treatment [27]. In addition, Dammann et al.
reported that rebamipide reduces gastric injury in individuals
taking high-dose aspirin (1,500 mg/day) [20]. However,
the efficacy of rebamipide in preventing low-dose aspirin-
induced gastrointestinal complications has remained un-
explored. We therefore tested it as a candidate drug for the
prevention of low-dose aspirin-induced gastric injury.
In the present study, rebamipide significantly prevented
low-dose aspirin-induced erythema in the antrum compared
Table 2. Endoscopic evaluation in antrum.
Lanza score
erythema erosion petechiae
Placebo Rebamipide Placebo Rebamipide Placebo Rebamipide
n =( % ) n = (%) n = (%) n = (%) n = (%) n =( % )
antrum 0 11/20 17/20 9/20 13/20 15/20 17/20
(55.0) (85.0) (45.0) (65.0) (75.0) (85.0)
1 6 / 2 03 / 2 06 / 2 03 / 2 04 / 2 03 / 2 0
(30.0) (15.0) (30.0) (15.0) (20.0) (15.0)
2 3 / 2 00 / 2 02 / 2 01 / 2 01 / 2 00 / 2 0
(15.0) (0.0) (10.0) (5.0) (5.0) (0.0)
3 0 / 2 00 / 2 03 / 2 03 / 2 00 / 2 00 / 2 0
(0.0) (0.0) (15.0) (15.0) (0.0) (0.0)
p-value 0.0393 0.5538 0.3105
Table 3. Endoscopic evaluation in body and fornix.
Lanza score
erythema erosion petechiae
Placebo Rebamipide Placebo Rebamipide Placebo Rebamipide
n =( % ) n = (%) n = (%) n = (%) n = (%) n =( % )
body 0 13/20 15/20 16/20 13/20 16/20 16/20
(65.0) (75.0) (80.0) (65.0) (80.0) (80.0)
1 7 / 2 04 / 2 02 / 2 04 / 2 03 / 2 02 / 2 0
(35.0) (20.0) (10.0) (20.0) (15.0) (10.0)
2 0 / 2 01 / 2 01 / 2 00 / 2 00 / 2 01 / 2 0
(0.0) (5.0) (5.0) (0.0) (0.0) (5.0)
3 0 / 2 00 / 2 01 / 2 03 / 2 01 / 2 01 / 2 0
(0.0) (0.0) (5.0) (15.0) (5.0) (5.0)
p-value 0.3076 0.3308 0.6622
fornix 0 17/20 16/20 18/20 19/20 18/20 20/20
(85.0) (80.0) (90.0) (95.0) (90.0) (100.0)
1 3 / 2 04 / 2 02 / 2 00 / 2 01 / 2 00 / 2 0
(15.0) (20.0) (10.0) (0.0) (5.0) (0.0)
2 0 / 2 00 / 2 00 / 2 01 / 2 01 / 2 00 / 2 0
(0.0) (0.0) (0.0) (5.0) (5.0) (0.0)
3 0 / 2 00 / 2 00 / 2 00 / 2 00 / 2 00 / 2 0
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
p-value 0.6769 0.1233 0.2372S. Ono et al.
J. Clin. Biochem. Nutr.
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with placebo (p<0.05) (Table 2). Naito et al. demonstrated
that lipid peroxidation mediated by oxygen radicals and
activated neutrophil play a crucial role in the pathogenesis
of NSAID-induced gastropathy. Rebamipide showed the
inhibitory of these parameters [28]. On the other hands, it is
well known that reduction of gastric mucosal blood flow
(GMBF) induces gastrointestinal disorders [29]. Rebamipide
prevented NSAID-induced gastric mucosal injury by
maintaining GMBF [30]. Administration of low-dose aspirin
frequently induced gastric mucosal injury in the antrum in
the control group, though the degree of injury was slight
(Table 2). On the other hand, administration of low-dose
aspirin did not induce injury in the body and fornix
(Table 3). This finding suggests that low-dose aspirin-
induced gastric mucosal injury occurs to a slight extent in
the antrum but not in the body or fornix. Asaki et al. demon-
strated that NSAID-induced gastric ulcers are concentrated
in the pyloric region to the antrum, regions which account
for three-fourths of all cases of ulcer in the stomach [31].
On the other hand, Daniel et al. have reported that admin-
istration of aspirin (900 mg/day) induced more mucosal
erosions and submucosal hemorrhages in the antrum than in
the fundus (p<0.05) [32]. Gastrokine 1, one of the most
abundant transcripts in normal stomach, is down-regulated
by H. pylori infection. G. Martin et al. demonstrated that
the use of low-dose aspirin led to a significant decrease
(3.07 a.u. vs 0.23 a.u., p<0.001) in antrum at day 7, while
Gastrokine 1 transcript levels in corpus mucosa were
slightly elevated (twofold, p<0.005). This data demonstrated
that low-dose aspirin down-regulates Gastrokine 1 expres-
sion specifically in antral mucosa, and induces gastro-
intestinal injuries in antrum [33]. A strategy to prevent
low-dose aspirin-induced gastric injuries in the antrum
will thus be needed. In addition, many patients undergoing
low-dose aspirin treatment are asymptomatic. Sudden
hospitalization due to bleeding is a serious problem. In our
study, all subjects were asymptomatic (data not shown).
Aging of society is progressing in Japan, and the number of
low-dose aspirin users will correspondingly be increasing.
In addition, periodic endoscopic examination will be needed
to detect serious gastrointestinal diseases other than bleeding
and ulcer, such as gastric cancer, because of the high pre-
valence of gastric malignancy in Japan.
Our study has several limitations. It was performed with
only short-term administration of low-dose aspirin and was
small in size. Although long-term administration of low-
dose aspirin is associated with an increased risk of lethal
upper gastrointestinal bleeding, the cumulative risk of upper
gastrointestinal bleeding is still very low. A large 5-year
observational Danish cohort study assessed hospitalization
for gastrointestinal bleeding with low-dose aspirin [34]. The
incidence of hospitalization for gastrointestinal bleeding
was 0.6% per year for individuals taking aspirin alone. It
was thus difficult to detect serious cases, such as bleeding,
in our small, short-term study. Our study used a mucosal
injury grading system (erosion, erythema, and petechia).
Evaluation with this grading system is not clinically
sufficient. Taking of high-dose aspirin induces submucosal
hemorrhages and gastrointestinal ulcers with frequently,
however most of low-dose aspirin-induced gastrointestinal
injuries are just slight, such as erythema, erosions, and
petechiae [31]. These slight injuries may progress to serious
injuries, such as ulcer, bleeding, and perforation, under
the chronic aspirin use and the additional risk factors that
are induced gastropathy, although there is no evidence to
resolve about this process. Since findings on patients with
long-term use of low-dose aspirin are quite limited, larger
long-term clinical research on patients with low-dose aspirin
is needed.
In conclusion, administration of short-term low-dose
aspirin induced slight gastric mucosal injury in the antrum,
but not in the body or fornix. Rebamipide may be useful for
the prevention of low-dose aspirin-induced gastric mucosal
injury, especially which confined to the antrum.
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